English/中文

Product Site

PharmaBlock Attended APRDL 2018 on Invitation to Deliver a Keynote Speech

2018-04-20


SPOTLIGHT


PharmaBlock Sciences (Nanjing), Inc. attended The Asia Pharma R&D Leaders Summit 2018 (APRDL 2018) in Shanghai from April 17th to April 18th in 2018. Dr. Haijun Dong, Chief Executive Officer of the company, was invited to deliver a keynote speech on how to apply enabling building blocks to support and accelerate drug discovery. Dr. Dong , together with heads of Chemistry and R&D from domestic and international leading pharmaceutical and biotechnology companies including BeiGene, Amgen, as well as Merck & Co. Inc., shed light on promoting drug discovery and development through innovative collaboration.


ABOUT APRDL 2018


The Asia Pharma R&D Leaders Summit 2018 (APRDL 2018) was sponsored by Deliver Life Science and supported by Sino-American Pharmaceutical Professionals Association- Greater Philadelphia (SAPA-GP) and The BayHelix Group (BayHelix). Leaders and senior representatives from more than 300 government regulatory agencies, industry associations, academic institutions, hospitals, pharmaceutical companies, biotechnology corporations and the like were invited to jointly discuss a wide range of topics such as global cutting-edge technology and latest development of new drug research and development, innovation-driven development strategy of China, open R & D cooperation scheme and the like.


Dr. Haijun Dong of PharmaBlock is delivering a keynote speech

"Of all the compounds that fail at different stages of clinical trials, approximately 70% are due to a lack of sufficient potency or unacceptable toxicity or side effects, which ultimately depends on the molecular structures of the candidate. We have more than 30,000 building blocks that have been widely adopted by hundreds of drug R & D organizations around the world to optimize structures of candidate compounds by improving various properties, such as drug potency, cardiotoxicity, metabolic stability and solubility etc. Our chemists keep tracking the latest research development and patents released on a daily base and take quick action to design and synthesize innovative building blocks."


Dr. Haijun Dong, CEO of PharmaBlock, Dr. Joseph Duffy, Executive Director of and Head of External Discovery Chemistry at Merck Research Lab, Dr. Changyou Zhou, Senior VP and Executive Head of Chemistry at BaiGene, and Dr. Wenge Zhong, Senior Director and Head of Discovery Modalities at Amgen Asia R&D Center, shared opinion on how to promote drug discovery and development through collaborative innovation


Dr. Joseph Duffy:

 "How do you interpret the value of PharmaBlock in collaboration with R&D driven pharmaceutical companies?"


Dr. Haijun Dong: 

"PharmaBlock started with providing lab-scale building blocks and medicinal chemistry services at early stages of drug discovery to support development and optimization of hit and lead generation. Over the past years, we have witnessed a number of projects adopting our building blocks being carried out step by step, from early stages of discovery to preclinical and clinical research, even to commercial manufacturing. We consider ourselves an indispensable partner to our customers’ projects rather than merely a provider of one or more products. Everything we do, we essentially do it in the hope of assisting our customers in finding better molecules more promptly. In the past few years, we have been continuously strengthening our technical competence in the field of process chemistry and building up some specialized technology labs capable of a series of advanced technologies including flow chemistry, photochemistry, biological catalysis, fluorination technologies and so forth. Among almost 1000  kilo-scale projects completed in 2017, many have put these new technologies into use. Furthermore, quite a lot of projects involve one or more demanding chemical reactions or technical challenges."